```html

Xanthosis (Cutaneous)

Overview

Xanthosis (also called cutaneous xanthosis or skin xanthoma) refers to the development of yellow‑orange plaques or nodules within the skin caused by the accumulation of lipid‑laden macrophages (foamy histiocytes). Although “xanthosis” can describe yellow discoloration of other tissues (e.g., corneal xanthoma), the cutaneous form is most often linked to underlying disorders of lipid metabolism, liver disease, or certain hematologic conditions.

Typical demographics:

• Age: Can appear at any age, but pediatric cases are frequently associated with familial hypercholesterolemia, while adult‑onset forms often accompany metabolic syndrome or liver disease.
• Sex: Slight male predominance (≈55 % of reported cases) likely reflects higher rates of dyslipidemia in men.
• Prevalence: Exact population prevalence is unknown because xanthomas are usually reported as a sign of another disease. However, skin xanthomas are found in ~2‑5 % of patients with familial hypercholesterolemia and in ~10‑15 % of individuals with severe chronic liver disease (e.g., cirrhosis) [1][2].

Symptoms

The clinical picture varies with the type of xanthoma (tuberous, tendinous, eruptive, plane, or nodular). Below is a consolidated list of cutaneous findings.

Typical Skin Manifestations

• Yellow‑orange plaques or nodules: Soft to firm, well‑circumscribed lesions that may be flat (plane) or raised (tuberous, nodular).
• Location: Common sites include elbows, knees, hands, buttocks, eyelids (xanthelasma), and over tendons (achilles, extensor tendons of the hand).
• Size: Ranges from a few millimeters (eruptive xanthomas) to several centimeters (tuberous xanthomas).
• Texture: May feel rubbery, papery, or slightly gritty.
• Number: Single lesions are possible, but most patients present with multiple lesions.
• Surface changes: Some lesions develop a thin, wrinkled “peau d’orange” appearance or become ulcerated if traumatized.

Associated Systemic Symptoms

• Fatigue or weakness (often from underlying metabolic disease).
• Abdominal discomfort or jaundice if liver disease is present.
• Chest pain or claudication in severe atherosclerotic disease.

Causes and Risk Factors

Xanthosis is not a primary disease; it is a skin manifestation of lipid deposition. The underlying causes fall into three broad categories:

1. Primary Lipid Metabolism Disorders

• Familial hypercholesterolemia (FH): Autosomal dominant mutations in LDLR, APOB, or PCSK9; prevalence ≈1 in 250 people worldwide.
• Familial combined hyperlipidemia: Elevations in LDL‑C, triglycerides, or both.
• Familial dysbetalipoproteinemia (type III hyperlipoproteinemia): ApoE2/E2 genotype; classic association with eruptive and plane xanthomas.

2. Secondary Causes (Acquired)

• Chronic liver disease: Cirrhosis, hepatitis B/C, non‑alcoholic steatohepatitis (NASH); impaired clearance of lipoproteins leads to lipid‑rich macrophage infiltration.
• Nephrotic syndrome: Protein loss triggers hepatic overproduction of lipoproteins.
• Diabetes mellitus: Particularly type 2 with poor glycemic control.
• Obesity and metabolic syndrome: Elevated triglycerides and low‑density lipoprotein (LDL) levels increase risk.
• Medications: Long‑term corticosteroids, retinoids, or protease inhibitors can raise lipid levels.

3. Hematologic and Other Disorders

• Langerhans cell histiocytosis: Rarely presents with cutaneous xanthomatous lesions.
• Myeloproliferative disorders: Excessive lipid release from malignant cells.

Risk Factors

• Family history of hyperlipidemia or early‑onset cardiovascular disease.
• Uncontrolled diabetes or hypertension.
• Excessive alcohol consumption (promotes liver disease).
• Smoking (worsens dyslipidemia).
• Obesity (BMI ≥ 30 kg/m²).

Diagnosis

Diagnosis is a two‑step process: clinical recognition of the skin lesions and identification of the systemic cause.

1. Clinical Examination

• Visual inspection and palpation of lesions.
• Distribution pattern helps differentiate subtypes (e.g., tendinous vs. eruptive).

2. Laboratory Evaluation

• Lipid panel: Total cholesterol, LDL‑C, HDL‑C, triglycerides.
• Liver function tests (ALT, AST, GGT, bilirubin): Assess hepatic contribution.
• Renal panel: Proteinuria, serum albumin for nephrotic syndrome.
• Glucose/HbA1c: Screen for diabetes.
• Genetic testing: When familial hypercholesterolemia is suspected (LDLR, APOB, PCSK9).

3. Imaging (when indicated)

• Ultrasound or elastography for liver fibrosis.
• Cardiovascular imaging (coronary CT, carotid Doppler) if high atherosclerotic risk.

4. Skin Biopsy

Definitive diagnosis is confirmed by histopathology:

• Hematoxylin‑eosin (H&E) stain shows sheets of foamy macrophages within the dermis.
• Special stains (Oil Red O, Sudan III) highlight intracellular lipids.
• Immunohistochemistry (CD68⁺) confirms macrophage origin.

Treatment Options

Treatment goals are two‑fold: remove or reduce skin lesions and correct the underlying metabolic disturbance.

1. Addressing the Underlying Cause

• Lipid‑lowering therapy:
  • Statins (e.g., atorvastatin 20‑80 mg daily) – first‑line for most dyslipidemias.
  • Ezetimibe – added when statins alone are insufficient.
  • PCSK9 inhibitors (alirocumab, evolocumab) – especially for heterozygous or homozygous FH.
  • Fibrates (gemfibrozil, fenofibrate) – useful in high‑triglyceride states.
  • Niacin – limited use due to side‑effects.
• Management of liver disease: Antiviral therapy for hepatitis, weight loss for NASH, abstinence from alcohol.
• Control of diabetes: Metformin, GLP‑1 agonists, SGLT2 inhibitors; tight glycemic control reduces lipid abnormalities.
• Renal disease treatment: ACE inhibitors/ARBs to reduce proteinuria.

2. Direct Dermatologic Therapies

• Topical treatments: Limited efficacy; topical retinoids may slightly improve plane xanthomas.
• Laser therapy: CO₂ or Nd:YAG laser can vaporize superficial lesions; multiple sessions often required.
• Cryotherapy: Useful for small eruptive papules.
• Surgical excision: Considered for large, symptomatic tuberous xanthomas, especially over joints where they limit movement.
• Intralesional steroids: Occasionally used to reduce inflammation in ulcerated lesions.

3. Lifestyle Modifications

• Adopt a heart‑healthy diet – Mediterranean pattern, ≤ 30 % of calories from fat, emphasis on omega‑3 fatty acids.
• Engage in regular aerobic exercise (≥150 min/week moderate intensity).
• Maintain optimal weight (BMI < 25 kg/m²).
• Avoid tobacco and limit alcohol (≤ 1 drink/day for women, ≤ 2 drinks/day for men).

Living with Xanthosis (cutaneous)

Daily Management Tips

• Skin care: Use mild, fragrance‑free cleansers; moisturize daily to prevent dryness and cracking.
• Protect lesions: Padding or protective footwear for xanthomas over pressure points (e.g., elbows, knees).
• Monitor lesion changes: Photograph lesions every 3‑6 months to detect growth or ulceration.
• Medication adherence: Set alarms or use pillboxes for lipid‑lowering and chronic disease meds.
• Regular follow‑up: Lipid panel every 3‑6 months initially, then annually if stable. Liver/renal labs as indicated.
• Psychosocial support: Cosmetic concerns are common; counseling or support groups can be beneficial.

Impact on Quality of Life

Visible lesions, especially on the face or hands, may cause embarrassment or social withdrawal. Early dermatologic intervention combined with effective systemic therapy often leads to partial or complete regression of lesions, improving self‑esteem.

Prevention

Because xanthosis reflects underlying metabolic dysfunction, primary prevention focuses on reducing those risk factors.

• Screening: Lipid panel at least once between ages 20‑30, then every 5 years, or earlier if family history.
• Genetic counseling: For families with known FH to initiate cascade testing.
• Healthy lifestyle from childhood: Balanced diet, physical activity, limited screen time.
• Vaccination against hepatitis B and C screening: Prevent liver disease that can precipitate secondary xanthosis.
• Medication review: Discuss with a physician any drugs that raise lipids (e.g., high‑dose steroids).

Complications

If the underlying metabolic abnormality is left untreated, patients are at higher risk for:

• Atherosclerotic cardiovascular disease: MI, stroke, peripheral arterial disease (leading cause of mortality in FH).
• Liver decompensation: Progression to cirrhosis, hepatocellular carcinoma.
• Pancreatitis: Particularly with severe hypertriglyceridemia.
• Joint impairment: Large tuberous xanthomas over joints can limit range of motion.
• Secondary infection: Ulcerated or traumatized lesions may become cellulitic.

When to Seek Emergency Care

---

References

1. Mayo Clinic. "Familial hypercholesterolemia." Updated 2023. https://www.mayoclinic.org
2. American Association for the Study of Liver Diseases. "Non‑Alcoholic Fatty Liver Disease (NAFLD) Guidelines." 2022.
3. National Heart, Lung, and Blood Institute. "Statins: How do they work?" 2021. https://www.nhlbi.nih.gov
4. World Health Organization. "Global report on diabetes." 2021.
5. Cleveland Clinic. "Xanthomas – Types, Causes, Treatment." Accessed May 2026.
6. U.S. Centers for Disease Control and Prevention. "High Blood Cholesterol Facts." 2022.

```